Comments on &quot;Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis&quot;. by Pellerito, S. & Tarantini, Francesca
Letters to the Editor
Comments on “Blockade of Angiogenesis by Small Molecule
Antagonists to Protease-Activated Receptor-1: Association
with Endothelial Cell Growth Suppression and Induction
of Apoptosis”
Received September 18, 2007; accepted October 9, 2007
This letter is in response to the report by Zania et al.
(2006). The authors used in vitro (Matrigel) and in vivo
(chick chorioallantoic membrane) models of angiogenesis
to demonstrate that small molecule PAR1 antagonists,
SCH79797 and RWJ56110, block formation of new blood
vessels through their ability to inhibit PAR1-mediated
signal transduction. They also showed that SCH79797
and RWJ56110 inhibit HUVEC proliferation and induce
apoptosis when the cells are grown in the presence of 4%
serum (FBS).
We would like to point out that SCH79797 is able to
inhibit cell proliferation and induce apoptosis in vitro in a
PAR1-independent manner. Di Serio et al. (2007) demon-
strated that SCH79797 (starting from a concentration of
100 nM) interferes with the growth of several human and
mouse cell lines, including PAR1 null fibroblasts, when the
cells are stimulated to grow with 10% serum, FGF-2 (25
ng/ml), or PDGF (20 ng/ml), whereas hirudin has no effect
on the ability of these cells to grow in culture. Because
neither FGF-2 nor PDGF depends on PAR1 receptor acti-
vation for its mitogenic effect, the ability of SCH79797 to
inhibit cell proliferation under these experimental condi-
tions is not likely to depend on its PAR1-blocking activity.
Moreover, the ability of this drug to inhibit the growth of
PAR1 null cells validates the hypothesis of a PAR1-inde-
pendent biological effect of this molecule. We now have
tested the growth inhibitory effect of SCH79797 on
HUVEC, stimulated in culture by 10% serum (FBS) or
FGF-2 (25 ng/ml), and found a significant inhibition of cell
growth in both experimental conditions (see Fig. 1). Zania
et al. (2006) reported that, in HUVEC treated with PAR1
inhibitors, phosphorylation of extracellular signal-regu-
lated kinase 1/2 stimulated by thrombin and 4% serum is
reduced. However, they found no effects on FGF-2, vascular
endothelial growth factor (VEGF), and epidermal growth fac-
tor-mediated extracellular signal-regulated kinase 1/2 acti-
vation. They presented this finding to indicate a specific
effect of the inhibitors on PAR1-mediated mitogen-activated
protein kinase activation. However, when we characterized
the growth inhibitory effect of SCH79797, we found that the
inhibitor was able to reduce phosphorylation of mitogen-
activated protein kinase induced by 10% serum, but not
FGF-2 or PDGF, although it was still able to block the ability
of all growth factors to induce cell proliferation (data not
shown). It will be of interest to test the ability of PAR1 small
inhibitors to block FGF-2- or VEGF-stimulated angiogenesis
in vitro and in vivo.
We have demonstrated that higher concentrations of the
inhibitor (200 nM) induce apoptosis in all of the cell lines
tested, including PAR1 null fibroblasts (Di Serio et al.,
2007). Zania et al. (2006) reported that the antiangiogenic
effect of SCH79797 is evident in fast-growing cultures of
HUVEC (50–60% confluency) but less pronounced in qui-
escent cells (100% confluency), which they interpreted to
indicate an effect of the inhibitor only on “activated” en-
dothelial cells involved in angiogenesis. However, we dem-
onstrated that the growth inhibitory effect of SCH79797
depends on cell density. Cells seeded at higher density still
respond to increasing concentrations of the inhibitor
(Di Serio et al., 2007).
We have little information regarding the cellular effects
of RWJ56110; however, we now have tested this molecule
against the ability of PAR1 null fibroblasts to grow in
culture and found that, like SCH79797, RWJ56110 signif-
icantly impairs the proliferative potential of these cells
(Fig. 2).
In conclusion, we suggest that the results reported by
Zania et al. (2006) are not conclusive for an antiangiogenic
effect of SCH79797 solely dependent on its ability to in-
hibit PAR1-mediated intracellular signal. Although we
agree that SCH79797 and RWJ56110 may be useful as
antiangiogenic agents and should be further developed for
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ABBREVIATIONS: PAR1, proteinase-activated receptor 1; SCH79797, N-3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]-methyl}-7H-pyrrolo[3,2-f]-
quinazoline-1,3-diamine)); RWJ56110, [(S)-N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-[[[[[1-(2,6-dichlorophenyl)methyl]-3-(1-pyr-
rolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluorobenzenepropanamide]; FGF-2, fibroblast growth factor-2; FBS, fetal bovine se-
rum; HUVEC, human umbilical vein endothelial cell(s); PDGF, platelet-derived growth factor.
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therapeutic applications, there is data to support that
their biological effect is, at least in part, independent from
PAR1 inhibition.
Department of Critical Care Medicine,
Geriatric Medicine Unit,
University of Florence
Florence, Italy
C. DI SERIO,
S. PELLERITO,
F. TARANTINI
References
Di Serio C, Pellerito S, Duarte M, Massi D, Naldini A, Cirino G, Prudovsky I,
Santucci M, Geppetti P, Marchionni N, et al. (2007) Protease-activated receptor 1
selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by
a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol
Toxicol 101:63–69.
Zania P, Kritikou S, Flordellis CS, Maragoudakis ME, Tsopanoglou NE (2006)
Blockade of angiogenesis by small molecule antagonists to protease-activated
receptor-1: association with endothelial cell growth suppression and induction of
apoptosis. J Pharmacol Exp Ther 318:246–254.
0
1
2
3
4
5
6
n.
 c
el
ls
(x
10
4 )
day 3
0
4
8
12
16
20
n.
 c
el
ls
(x
10
4 )
day 3
p<0.0001
p<0.0001
NS
p<0.02
FGF-2 (25ng/ml)+ hirudin (2.5U/ml)
+ vehicle (DMSO 50 mM)
FGF-2 (25ng/ml)+ hirudin (2.5U/ml)
+ SCH79797 (300 nM)
FGF-2 (25ng/ml)+ hirudin (2.5U/ml)
+ SCH79797 (1 µ M)
0% FBS 10% FBS
Fig. 1. HUVEC cells (2  104 cells/well) were plated in triplicates and grown in M199 containing 10% FBS or no serum in the presence of 25 ng/ml
FGF-2, 2.5 U/ml hirudin, and SCH79797 (300 nM and 1 M). Cells were counted at day 3 using an hemocytometer. Data are presented as mean 
S.D. DMSO, dimethyl sulfoxide.
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Fig. 2. PAR1 null fibroblasts (2  104 cells/well)
were plated in triplicates and grown in Dulbec-
co’s modified Eagle’s medium containing 10%
FBS, in the presence of RWJ56110 (0.1, 1, and
50 M). Cells were counted at day 3 using an
hemocytometer. Data are presented as mean 
S.D. DMSO, dimethyl sulfoxide.
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